Claims for Patent: 10,100,106

Summary for Patent: 10,100,106

Title:	Single domain serum albumin binding protein
Abstract:	Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
Inventor(s):	Dubridge; Robert B. (Belmont, CA), Lemon; Bryan D. (Mountain View, CA), Austin; Richard J. (San Francisco, CA), Evnin; Luke (San Francisco, CA), Guenot; Jeanmarie (San Francisco, CA)
Assignee:	HARPOON THERAPEUTICS, INC. (South San Francisco, CA)
Application Number:	15/600,582
Patent Claims:	1. A single domain serum albumin binding protein, comprising complementarity determining regions CDR1, CDR2, and CDR3, wherein (a) the amino acid sequence of CDR1 is as set forth in GFX.sub.1X.sub.2X.sub.3X.sub.4FGMS (SEQ ID NO. 1), X.sub.1 is threonine, arginine, lysine, serine, or proline, X.sub.2 is phenylalanine or tyrosine, X.sub.3 is serine, arginine or lysine, X.sub.4 is serine, lysine, arginine, or alanine; (b) the amino acid sequence of CDR2 is as set forth in SISGSGX.sub.5X.sub.6TLYAX.sub.7SX.sub.8K (SEQ ID NO. 2), X.sub.5 is serine, arginine, threonine, or alanine, X.sub.6 is aspartic acid, histidine, valine, or threonine, X.sub.7 is aspartic acid, histidine, arginine, or serine, X.sub.8 is valine or leucine; and (c) the amino acid sequence of CDR3 is as set forth in GGSLX.sub.9X.sub.10 (SEQ ID NO. 3), X.sub.9 is serine, arginine, threonine, or lysine, and X.sub.10 is arginine, lysine, valine, proline, or asparagine, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.8, X.sub.9, and X.sub.10 are not simultaneously threonine, phenylalanine, serine, serine, serine, aspartic acid, aspartic acid, valine, serine, and arginine, respectively. 2. The single domain serum albumin binding protein of claim 1, wherein said protein comprises the following formula: f1-r1-f2-r2-f3-r3-f4 wherein, r1 is SEQ ID NO. 1; r2 is SEQ ID NO. 2; and r3 is SEQ ID NO. 3; and f.sub.1, f.sub.2, f.sub.3 and f.sub.4 are framework residues selected so that said protein is at least eighty percent identical to the amino acid sequence set forth in SEQ ID NO. 10. 3. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 14, SEQ ID NO. 15 or SEQ ID NO. 16. 4. The single domain serum albumin binding protein of claim 2, wherein r2 comprises SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, or SEQ ID NO. 22. 5. The single domain serum albumin binding protein of claim 2, wherein r3 comprises SEQ ID NO. 23 or SEQ ID NO. 24. 6. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 14. 7. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 15, r2 is SEQ ID NO. 17, and r3 is SEQ ID NO.23. 8. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 16, r3 comprises SEQ ID NO. 23. 9. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 15 and r2 comprises SEQ ID NO. 18. 10. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 14 and r3 comprises SEQ ID NO. 23. 11. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 15, r2 comprises SEQ ID NO. 19 and r3 comprises SEQ ID NO. 24. 12. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 14 and r2 comprises SEQ ID NO. 20. 13. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 15, and r2 comprises SEQ ID NO. 21. 14. The single domain serum albumin binding protein of claim 2, wherein r1 comprises SEQ ID NO. 15, r2 comprises SEQ ID NO. 22 and r3 comprises SEQ ID NO. 24. 15. The single domain serum albumin binding protein of claim 1, wherein said protein has an amino acid sequence selected from SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ IN NO. 25, SEQ ID NO. 26, and SEQ ID NO. 27. 16. The single domain serum albumin binding protein of claim 15, wherein said protein comprises the amino acid sequence set forth as SEQ ID NO. 4. 17. The single domain serum albumin binding protein of claim 15, wherein said protein comprises the amino acid sequence set forth as SEQ ID NO. 7. 18. The single domain serum albumin binding protein of claim 15, wherein said protein comprises the amino acid sequence set forth as SEQ ID NO. 9. 19. The single domain serum albumin binding protein of claim 15, wherein said protein comprises the amino acid sequence set forth as SEQ ID NO. 26. 20. The single domain serum albumin binding protein of claim 15, wherein said protein comprises the amino acid sequence set forth as SEQ ID NO. 27. 21. The single domain serum albumin binding protein of claim 1, wherein said protein binds to mouse serum albumin with a binding affinity (Kd) that is about 1.5 fold to about 20 fold weaker than the binding affinity (Kd) of said protein towards human and cynomolgus serum albumin. 22. The single domain serum albumin binding protein of claim 21, wherein said protein binds to human serum albumin with a human Kd (hKd), to cynomolgus serum albumin with a cynomolgus Kd (cKd), and wherein ratio between the hKd and cKd (hKd cKd) ranges from about 20:1 to about 1:2. 23. The domain serum albumin binding protein of claim 1, wherein said protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours. 24. A single domain serum albumin binding protein comprising CDR1, CDR2, and CDR3, comprising the sequence set forth as SEQ ID NO. 10 (wt anti-HSA) wherein one or more amino acid residues selected from amino acid positions 28, 29, 30, or 31 of CDR1; positions 56, 57, 62, or 64 of CDR2; and positions 103, and 104 of CDR3 are substituted, wherein amino acid position 28 is substituted with arginine, lysine, serine, or proline, amino acid position 29 is substituted with tyrosine, amino acid position 30 is substituted with arginine or lysine, amino acid position 31 is substituted with lysine, arginine, or alanine, amino acid position 56 is substituted with arginine, threonine, or alanine, amino acid position 57 is substituted with histidine, valine, or threonine, amino acid position 62 is substituted with histidine, arginine, glutamic acid, or serine, amino acid position 64 is substituted with leucine, amino acid position 103 is substituted with arginine, threonine, or lysine, amino acid position 104 is substituted with lysine, valine, proline, or asparagine. 25. A method for the treatment or amelioration of a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease comprising the administration of the single domain serum albumin binding protein according to claim 1, to a subject in need thereof. 26. A multispecific binding protein comprising the single domain serum albumin binding protein according to claim 1.

Details for Patent 10,100,106

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	October 21, 1942	10,100,106	2036-05-20
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	March 03, 1954	10,100,106	2036-05-20
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	July 23, 1976	10,100,106	2036-05-20
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	August 15, 1978	10,100,106	2036-05-20
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	November 29, 2022	10,100,106	2036-05-20
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	February 17, 1995	10,100,106	2036-05-20